Synonyms: S-033188 | S033188 | Xofluza®
baloxavir marboxil is an approved drug (Japan & FDA (2018), EMA (2021))
Compound class:
Synthetic organic
Comment: Baloxavir marboxil is an orally delivered anti-influenza virus drug. It is a prodrug that is converted to baloxavir [1]. Mechanistically baloxavir is a first-in-class inhibitor of the cap-endonuclease (CEN) activity of an acidic protein within the viral polymerase complex [3] that is essential for viral gene transcription and replication. Alternative influenza antivirals (e.g. oseltamivir, peramivir and zanamivir) target the neuraminidase enzyme that is required for fusion and entry of virus into the host cells, and the budding process that releases newly synthesised virions.
|
|
No information available. |
Pharmacokinetics ![]() |
Biotransformation/Metabolism |
Baloxavir marboxil is converted via UDP glucuronosyltransferase family 1 member A3 (UGT1A3) and CYP3A4 to the active metabolite baloxavir. UGT1A3 is the major route to conversion. |
External links ![]() |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |